Alcobra Ltd (ADHD) was Initiated by Barclays to “Equal Weight” and the brokerage firm has set the Price Target at $8. Barclays advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on Alcobra Ltd. Alcobra Ltd was Resumed by ROTH Capital to “Buy” on Jun 21, 2016. Cantor Fitzgerald Initiated Alcobra Ltd on Jun 7, 2016 to “Buy”, Price Target of the shares are set at $16.
Alcobra Ltd (ADHD) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $4.28 and reached the intraday high at $4.29. The bulls started the profit booking and pushed the shares to intraday low of $4.16. The trading session was marked by a volume range of 32,983 shares exchanging hands. The 52-week high of the shares is $9.5 and the 52-week low is $3.15. The market cap of the company stands at $118 M and there are 2,75,60,920 shares in public circulation.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.